Clay Hatteras Venture Advis... Net Worth

The estimated Net Worth of Clay Hatteras Venture Advis... is at least $27.5 million dollars as of 22 May 2017. Clay Advis owns over 133,333 units of G1 Therapeutics Inc stock worth over $27,534,613 and over the last 7 years Clay sold GTHX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Clay Advis GTHX stock SEC Form 4 insiders trading

Clay has made over 1 trades of the G1 Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Clay bought 133,333 units of GTHX stock worth $1,999,995 on 22 May 2017.

The largest trade Clay's ever made was buying 133,333 units of G1 Therapeutics Inc stock on 22 May 2017 worth over $1,999,995. On average, Clay trades about 133,333 units every 0 days since 2017. As of 22 May 2017 Clay still owns at least 3,861,797 units of G1 Therapeutics Inc stock.

You can see the complete history of Clay Advis stock trades at the bottom of the page.

What's Clay Advis's mailing address?

Clay's mailing address filed with the SEC is 79 T W Alexander Drive #4501 Ste 100, Research Triangle Park, NC 27709, United States.

Insiders trading at G1 Therapeutics Inc

Over the last 8 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman et Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.

What does G1 Therapeutics Inc do?

g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.

Complete history of Clay Advis stock trades at G1 Therapeutics Inc

G1 Therapeutics Inc executives and stock owners

G1 Therapeutics Inc executives and other stock owners filed with the SEC include:

• Mark Avagliano,
  Chief Business Officer
• James Hanson,
  General Counsel, Secretary
• Mark Velleca,
  President, Chief Executive Officer, Director
• Terry Murdock,
  Chief Operating Officer
• Garry Nicholson,
  Independent Chairman of the Board
• Jennifer Moses,
  Chief Financial Officer
• Rajesh Malik,
  Chief Medical Officer, Senior Vice President - Research and Development
• Dr. Mark A. Velleca M.D., Ph.D.,
  Sr. Advisor & Director
• Mark Avagliano,
  Chief Bus. Officer
• Dr. Rajesh K. Malik Ch.B., M.B., M.D.,
  Chief Medical Officer and Sr. VP of R&D
• Dr. Rajesh K. Malik,
  Chief Medical Officer and Sr. VP of R&D
• Andrew Perry,
  Chief Commercial Officer
• Jennifer K. Moses CPA,
  Chief Financial Officer
• Jennifer K. Moses,
  Chief Financial Officer
• Seth Rudnick,
  Independent Director
• Glenn Muir,
  Independent Director
• Cynthia Schwalm,
  Independent Director
• Fredric Eshelman,
  Independent Director
• Willie Deese,
  Independent Director
• Andrew Witty,
  Independent Director
• John Bailey,
  Independent Director
• Soma Gupta,
  Chief Commercial Officer
• Jay Strum,
  Chief Scientific Officer
• Terry L. Murdock,
  Chief Operating Officer
• Blake Jensen,
  VP of Quality & Compliance
• William C. Roberts,
  VP of Investor Relations & Corp. Communications
• Dr. Jay C. Strum,
  Chief Scientific Officer
• Alexander D. Smith M.S.,
  VP of Technical Operations
• John E. Bailey Jr.,
  CEO, Pres & Director
• Clay Hatteras Venture Advis...,
  
• Capital Management, L.P.Ra ...,
  
• Christy L Shaffer,
  Director
• Ventures, Inc. Med Immune,
  10% owner
• Ventures, Llc Eshelman,
  10% owner
• Clay Hatteras Venture Advis...,
  
• Barclay A Phillips,
  SVP & Chief Financial Officer
• Monica R. Thomas,
  Chief Legal & People Officer
• Jacks Lee,
  
• John Demaree,
  Chief Commercial Officer
• Alicia Secor,
  
• Cynthia Louise Flowers,
  
• Andrew Perry,
  Chief Commercial Officer
• Norman Sharpless,
  
• John W. V Umstead,
  Chief Financial Officer